Decoy oligodeoxynucleotides targeting STATs in non-cancer gene therapy


Mahjoubin-Tehran M., Rezaei S., Kesharwani P., KARAV S., Sahebkar A.

Gene, vol.957, 2025 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 957
  • Publication Date: 2025
  • Doi Number: 10.1016/j.gene.2025.149482
  • Journal Name: Gene
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aquatic Science & Fisheries Abstracts (ASFA), Artic & Antarctic Regions, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, Food Science & Technology Abstracts, Veterinary Science Database
  • Keywords: Cell processes, Decoy oligodeoxynucleotides, Signal transducer, STAT, STAT3
  • Çanakkale Onsekiz Mart University Affiliated: Yes

Abstract

The Signal Transducer and Activator of Transcription (STAT) protein family is crucial for organizing the epigenetic configuration of immune cells and controlling various fundamental cell physiological functions including apoptosis, development, inflammation, immunological responses, and cell proliferation and differentiation. The human genome has seven known STAT genes, named 1, 2, 3, 4, 5a, 5b, and 6. Aberrant activation of STAT signaling pathways is associated with many human disorders, particularly cardiovascular diseases (CVDs), making these proteins promising therapeutic targets. Improved understanding of altered and pathological gene expression and its role in the pathophysiology of various hereditary and acquired disorders has enabled the development of novel treatment approaches based on gene expression modulation. One such promising development is the oligodeoxynucleotide decoy method, which may allow researchers to specifically influence gene activation or repression. Various oligodeoxynucleotide decoys target STATs and affect the expression of its downstream genes. We summarized cell culture and preclinical research, which evaluated the effects of oligodeoxynucleotide decoys target STATs in different types of non-cancer illnesses.